newsfilter
← Earnings
Earnings Releases·

Jaguar Health — Third Quarter 2026 Earnings Summary

  • Total net revenue declined 24.0% year-over-year to $2.343 million, driven by an 81.9% drop in product revenue to $551,000, partially offset by a 4,166.7% surge in license and grant revenue to $1.792 million.
  • Operating losses narrowed significantly, with net loss improving 39.6% to $5.830 million and non-GAAP EBITDA loss reducing to $5.590 million from $9.025 million in the prior year period.
  • Strategic focus has shifted to rare disease development with a plan to file an NDA for crofelemer powder for microvillus inclusion disease in mid-2027, supported by a U.S. commercial licensing agreement with Future Pak effective January 2026.
  • The company executed major capital and operational restructuring, including a $10.1 million debt reduction, a gain on debt extinguishment of $0.6 million, and the dissolution of the Jaguar/Napo Sales and Marketing Group to reduce operating expenses.
Company
JAGUAR HEALTH INC
Sector
Healthcare
Industry
Biotechnology